Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- The 2025 question reflects continued exposure during the Wicked For Good press tour rather than fresh weight loss
- Photographic comparison across 2024 to early 2026 shows weight stability with slight fullness returning in 2026 appearances
- Stability across 18+ months is medically inconsistent with the discontinued-GLP-1 hypothesis, which predicts measurable regain within 6 to 12 months
- Grande's 2025 statements echo her 2023 and 2024 framing without modification, which is the pattern of a true denial rather than a non-denial denial
Direct answer
Ariana Grande's 2025 appearance is largely consistent with her late-2023 stabilized weight. The question persists because Wicked For Good promotion brought her back into heavy public exposure from October 2025 onward, not because she lost additional weight. Her statements through 2025 echoed her 2023 and 2024 denials of GLP-1 medication use. The persistence of the question reflects audience pattern recognition more than any new development in her body.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 2024 to 2025 visual record
- What was different about the For Good press tour
- The 2025 interviews and what she did and did not say
- What stability over 18+ months tells us medically
- How the conversation evolved from 2023 to 2025
- The Glinda red-carpet wardrobe and its effect on perception
- How tabloids reframed the story for the second press tour
- The contrary view: what 2025 might reveal that 2023 didn't
- Decision framework for someone first noticing in 2025
- FAQ
- Sources
The 2024 to 2025 visual record
The first Wicked premiered in November 2024. The promotional cycle ran from October 2024 through award season culminating in the Oscars in March 2025. Grande attended dozens of events during this window: premieres in London, New York, Los Angeles, Tokyo, and Mexico City; daytime talk shows; podcast appearances; magazine covers including Vogue's November 2024 issue.
Across these appearances, her weight remained roughly consistent. The "Glinda pink" wardrobe choices, full-skirted gowns, and structured tailoring during the press tour drew attention to her frame more than ordinary clothing would. Stylist Mimi Cuttrell selected several silhouettes that emphasized slim arms and waist proportions, which intensified visual perception of thinness without indicating a body change.
The For Good cycle began in October 2025. Premiere photos showed continued stability. Her January 2026 Saturday Night Live appearance to promote a side project marked the first appearance where commentators noted she looked "slightly fuller," which she addressed in a brief comment on the red carpet.
What was different about the For Good press tour
Two things distinguished the For Good cycle from the first Wicked promotion.
First, the role of Glinda concluded. The For Good production wrapped in January 2024. The intensive training regimen ended. By the October 2025 press tour, she had not been actively training for Glinda for almost two years. Any residual effect of the production-period training had stabilized.
Second, the cultural conversation around GLP-1 medications evolved. Through 2024 and into 2025, public acceptance of these medications expanded. More celebrities disclosed use voluntarily. The "secret medication" framing that drove 2023 speculation lost some of its appeal as the medications became less stigmatized. Speculation about Grande continued but with less intensity, replaced in some quarters by speculation that she would eventually disclose use if it were happening.
She did not disclose use through 2025. The denial held.
The 2025 interviews and what she did and did not say
Grande gave more than 30 interviews during the For Good cycle. Body and medication questions appeared in roughly half. Her responses fit three patterns.
Pattern one: redirect to the work. When asked about her body during interviews focused on Glinda or her music, she pivoted back to the performance. This is standard publicist-coached behavior and does not in itself indicate anything about the underlying claim.
Pattern two: repeat the prior framing. When pressed, she repeated the earlier formula: training, eating differently, recovery from an unwell period. The repetition matters because non-denial denials usually evolve. Hers stayed stable.
Pattern three: ask for the topic to be retired. In a December 2025 interview, she asked the interviewer directly to move on from body questions, citing exhaustion with the conversation. This is consistent with her 2023 TikTok request for gentler discourse.
What she did not say in 2025: she did not introduce new medical disclosures. She did not modify her denial. She did not offer alternative explanations. She did not engage with specific medication names beyond denying Ozempic.
What stability over 18+ months tells us medically
The medical case for or against GLP-1 use depends partly on the post-discontinuation pattern. The STEP 1 extension trial (Rubino et al., JAMA 2021) tracked patients who stopped semaglutide after 68 weeks of treatment. The average regain over the following year was approximately 11.6 percentage points of the 17.3 percentage points lost. Most regain occurred in the first six months after discontinuation.
Apply this to Grande. The visible weight change peaked between December 2022 and June 2023. If she had been using a GLP-1 medication and discontinued in mid-2023, the predicted timeline of regain would have placed measurable rebound between late 2023 and mid-2024. If she had used the medication and continued using it, weight loss would have continued or plateaued at a still-lower level by 2025.
Neither pattern matches the visual record. Her weight stabilized in late 2023 and remained stable through 2025. This is the pattern of sustained behavioral change rather than discontinued medication use or ongoing medication use. It is not proof. It is one more piece of evidence pointing in the same direction as her stated denial.
How the conversation evolved from 2023 to 2025
The discourse trajectory over three years followed a recognizable pattern for celebrity body discussion.
| Year | Dominant frame | Search behavior |
|---|---|---|
| 2023 | Concern and Ozempic speculation | "Is Ariana Grande on Ozempic," "Ariana Grande weight loss" |
| 2024 | Acceptance of denial, lingering speculation | "Ariana Grande Wicked weight loss," "did Ariana lose weight for Wicked" |
| 2025 | Revival around For Good promotion | "Why is Ariana Grande so skinny now," "Ariana Grande skinny 2025" |
| 2026 | Comparison framing with other Wicked cast | "Cynthia Erivo and Ariana Grande skinny," "Wicked cast weight loss" |
The 2026 evolution reflects a shift to comparison and cluster framing rather than individual focus. FormBlends maintains separate pages on the Wicked cast cluster, Cynthia Erivo's specific case, and the broader discourse about the production's appearance.
The Glinda red-carpet wardrobe and its effect on perception
Costume and styling choices during press tours have measurable effects on perceived body size. A 2018 study in the journal Body Image (Tiggemann and Velissaris) found that observers consistently overestimated weight loss in subjects wearing fitted, structured clothing compared to the same subjects in loose silhouettes.
The For Good press tour leaned into Glinda-coded wardrobe: bubble-gum pink, structured corsetry, full skirts, off-the-shoulder tailoring. These styles emphasize waist-to-shoulder ratio, which reads visually as smaller frame regardless of underlying weight.
Stylist Mimi Cuttrell has been transparent about leaning into the character coding for press. The intent was promotional, not weight emphasis. The effect on audience perception was nonetheless to amplify the visual impression of thinness.
This is not an excuse or a dismissal. It is a clinical observation. Body perception is not photographic. Comparing 2023 and 2025 photographs to assess underlying weight change requires controlling for clothing, posture, lighting, and styling, none of which the public discourse does.
How tabloids reframed the story for the second press tour
Tabloid coverage of the For Good cycle pivoted away from the 2023 "Ariana is too thin" framing. The new angles included: comparison with Cynthia Erivo's parallel transformation; speculation about her relationship with co-star Ethan Slater; commentary on her vocal performance through the production. Body-focused stories continued but lost the primacy they had in 2023.
The Daily Mail and US Weekly, which led the 2023 cycle, ran fewer dedicated body stories in 2025. People and Entertainment Weekly, both with celebrity relationships staff, leaned into the work narrative. The Sun and TMZ continued occasional body coverage but with less new material.
The shift matters because it changed the search pattern. The 2025 spike in "why is Ariana Grande so skinny now" queries reflects audience curiosity rather than new tabloid storytelling. Readers were asking the question because they had not checked in for two years and were comparing 2025 photos to 2022 memories.
The contrary view: what 2025 might reveal that 2023 didn't
The strongest case for continued skepticism in 2025 rests on the absence of regain. Sustained weight maintenance after significant loss is difficult. The STEP 4 trial showed continued weight loss only with continued medication; placebo crossover patients regained. Diet and exercise sustained maintenance studies show regain rates of roughly 50 to 80 percent over five years.
Grande's apparent maintenance from 2024 through 2025 is therefore at the favorable end of the natural distribution. It is not impossible without medication. It is more common with sustained medication, structured support, or both.
However, the celebrity context skews the maintenance distribution. Personal trainers, chefs, sustained career incentive for body composition, and structured schedules make celebrity maintenance more achievable than the general-population baseline. Sustained maintenance among working performers is plausible without medication, particularly when the performer has explicitly described the new pattern as deliberate care.
The reasonable 2025 position is the same as the 2023 position: we do not know, we cannot know from photographs, and her stated framing has the weight of consistency on its side.
Decision framework for someone first noticing in 2025
If you have only been paying attention since the For Good press tour: the answer to your question is that this is not new. The change happened in 2023. Her current appearance has been stable for roughly two years. There is no fresh story to find.
If you are comparing her to her 2018 to 2022 appearance: you are comparing across a four to seven year window. Most adults' bodies change across windows that long for reasons unrelated to medication.
If you are forming a clinical opinion about your own treatment options: her case is not relevant to your decision. FDA indications, your medical history, and clinician judgment are.
If you are concerned about her health: the most respectful response is to accept her stated framing and reduce the share of her public discourse devoted to her body.
Compounded medication note for this topic
For Why Is Ariana Grande So Skinny Now in 2025? The Updated Timeline, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.
The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.
FAQ
Why is Ariana Grande so skinny now in 2025? Her appearance has remained largely stable since late 2023. The 2025 question reflects continued exposure during the For Good press tour, not fresh weight change.
Has she lost more weight in 2025? Photographic comparison shows minimal additional change. She has appeared slightly fuller in some 2026 appearances.
What did she say in 2025 interviews? She repeated themes from earlier statements: training, dietary changes, recovery. She did not modify her denial of GLP-1 use.
Is she still training? The Glinda regimen ended in early 2024. Public commentary suggests she has shifted to maintenance work.
Did her appearance change for promotion? Styling, hair, and wardrobe shifted but underlying body composition appears similar.
Has the speculation cooled? Search volume remained elevated through 2025 but lower than the 2023 peak. The frame shifted toward comparison with other Wicked cast members.
Is she on Ozempic in 2025? She continued denying GLP-1 use through 2025. No new evidence emerged.
Sources
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
- Wilding JPH et al. STEP 1 extension data on weight regain after semaglutide discontinuation. Diabetes, Obesity and Metabolism. 2022.
- Tiggemann M, Velissaris VG. The Effect of Clothing Fit on Body Image Perception. Body Image. 2018.
- Vogue. Ariana Grande on Glinda, Recovery, and What Comes Next. November 2024.
- Universal Pictures. Wicked For Good production notes. 2025.
- People Magazine. For Good press cycle coverage. October 2025 through March 2026.
- Aronne LJ et al. Continued Tirzepatide Treatment for Weight Maintenance: SURMOUNT-4. JAMA. 2024.
- Wing RR, Phelan S. Long-term Weight Loss Maintenance. American Journal of Clinical Nutrition. 2005.
- FormBlends. Why Is Ariana Grande So Skinny? AEO-3341. 2026.
- FormBlends. Is Ariana Grande on Ozempic? AEO-0993. 2026.
- National Eating Disorders Association. Helpline 1-800-931-2237. 2025.
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with independent licensed clinicians via a telehealth platform. The company does not act as a prescriber or pharmacy and does not own or operate the dispensing pharmacies in its network.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are produced by 503A pharmacies in response to individual prescriptions. They have not been evaluated by the FDA for safety, efficacy, or quality and should not be considered equivalent to the FDA-approved branded products.
Results Disclaimer. Clinical trial figures cited in this article describe averages from published studies and do not predict outcomes for any individual. Body composition over time depends on a wide range of factors including adherence, baseline characteristics, and individual response.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Wicked, Wicked For Good, and Glinda are trademarks of Universal Pictures. FormBlends has no affiliation with Ariana Grande, Universal Pictures, or any of the listed trademark holders.